scholarly journals Point‐of‐Care Testing in Sickle Cell Disease

10.5772/64862 ◽  
2016 ◽  
Author(s):  
Julie Kanter
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Point Of Care ◽  
Cell Disease ◽  
Point Of Care Testing

Preliminary Evaluation of a Point-of-Care Testing Device (SickleSCAN™) in Screening for Sickle Cell Disease

Hemoglobin ◽  
2017 ◽  
Vol 41 (2) ◽  
pp. 77-82 ◽  
Author(s):  
Maxwell M. Nwegbu ◽  
Hezekiah A. Isa ◽  
Biyaya B. Nwankwo ◽  
Chinedu C. Okeke ◽  
Uduak J. Edet-Offong ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Point Of Care ◽  
Preliminary Evaluation ◽  
Testing Device ◽  
Cell Disease ◽  
Point Of Care Testing

scholarly journals Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Low-Income Setting

PEDIATRICS ◽  
2019 ◽  
Vol 144 (4) ◽  
pp. e20184105 ◽  
Author(s):  
Ofelia A. Alvarez ◽  
Tally Hustace ◽  
Mimose Voltaire ◽  
Alejandro Mantero ◽  
Ulrick Liberus ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Newborn Screening ◽  
Sickle Cell ◽  
Low Income ◽  
Point Of Care ◽  
Cell Disease ◽  
Point Of Care Testing ◽  
Low Income Setting

scholarly journals Validation of a novel point of care testing device for sickle cell disease

BMC Medicine ◽  
2015 ◽  
Vol 13 (1) ◽  
Author(s):  
Julie Kanter ◽  
Marilyn J. Telen ◽  
Carolyn Hoppe ◽  
Christopher L. Roberts ◽  
Jason S. Kim ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Point Of Care ◽  
Testing Device ◽  
Cell Disease ◽  
Point Of Care Testing

scholarly journals Diagnostic Accuracy of HemotypeSC as a Point-of-Care Testing Device for Sickle Cell Disease: Findings from a Southwestern State in Nigeria and Implications for Patient Care in Resource-Poor Settings of sub-Saharan Africa

2021 ◽  
Vol 8 ◽  
pp. 2333794X2110167
Author(s):  
Oladele S. Olatunya ◽  
Dulcinea M. Albuquerque ◽  
Adeniyi F. Fagbamigbe ◽  
Opeyemi A. Faboya ◽  
Ayotunde E. Ajibola ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sensitivity And Specificity ◽  
Sickle Cell ◽  
Point Of Care ◽  
Sub Saharan Africa ◽  
Testing Device ◽  
Cell Disease ◽  
Point Of Care Testing ◽  
Predictive Values ◽  
Sub Saharan

This study aimed to determine the performance of a rapid, point-of-care testing device (HemotypeSC)™ for diagnosing sickle cell disease (SCD) relative to 2 commonly-used methods compared to DNA polymerase chain reaction (PCR) as the reference standard. The diagnostic performance of (HemotypeSC)™ in diagnosing SCD and determining various other Hb genotypes relative to high performance liquid chromatography (HPLC) and cellulose acetate Hb electrophoresis in alkaline buffer (CAE) was investigated among 156 participants aged 4 to 23 years in Ekiti, Southwest Nigeria. PCR was considered as the reference method/gold standard. The sensitivity and specificity for SS, SC, AS, AC, and AA genotypes by HemotypeSC and HPLC when compared with PCR, were each 100%. Similarly, their positive and negative predictive values were each 100%. However, sensitivity and specificity for identifying these Hb genotypes by CAE were 100, 100, 96.5, 0, 99.2%, and 99, 100, 92.9, 0, 91.7%. Also, CAE did not identify any of the 2 HbAC individuals that were correctly identified by PCR and both HemotypeSC, and HPLC, thus representing 100% HbAC misdiagnosis. In conclusion, this study shows that HemotypeSC has perfect concordance with PCR and 100% accuracy in diagnosing SCD in the population tested. Its ease of use, accuracy and other attributes make it suitable for use in sub-Saharan Africa for rapid determination of Hb genotypes.

Communicating sickle cell disease point-of-care testing results

2020 ◽  
Vol 7 (10) ◽  
pp. e708-e709
Author(s):  
Cheedy Jaja ◽  
Robert W Gibson ◽  
Joseph Edem-Hotah
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Point Of Care ◽  
Cell Disease ◽  
Point Of Care Testing

scholarly journals HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease: Promises and challenges

2019 ◽  
Vol 78 ◽  
pp. 22-28 ◽  
Author(s):  
Obiageli Nnodu ◽  
Hezekiah Isa ◽  
Maxwell Nwegbu ◽  
Chinatu Ohiaeri ◽  
Samuel Adegoke ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Point Of Care ◽  
Low Cost ◽  
Testing Device ◽  
Cell Disease ◽  
Point Of Care Testing

Multicenter Evaluation of HemoTypeSC as a Point-of-Care Sickle Cell Disease Rapid Diagnostic Test for Newborns and Adults Across India

2019 ◽  
Vol 153 (1) ◽  
pp. 82-87 ◽  
Author(s):  
Malay B Mukherjee ◽  
Roshan B Colah ◽  
Pallavi R Mehta ◽  
Nikhil Shinde ◽  
Dipty Jain ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Newborn Screening ◽  
Sickle Cell ◽  
High Performance ◽  
Screening Program ◽  
Point Of Care ◽  
Genetic Disorder ◽  
Cell Disease ◽  
Point Of Care Test ◽  
Tribal Areas

Abstract Objectives Sickle cell anemia is the commonest genetic disorder in India, and the frequency of the sickle cell gene is very high in the remote tribal areas where facilities are generally limited. Therefore, a rapid and affordable point-of-care test for sickle cell disease is needed. Methods The diagnostic accuracy of HemoTypeSC was evaluated against automated high-performance liquid chromatography (HPLC) as the gold standard for its efficacy in a newborn screening program. Results A total of 1,559 individuals (980 newborns and 579 adults) from four participating centers were analyzed by both methods. HemoTypeSC correctly identified 209 of 211 total hemoglobin (Hb) SS cases, for a 99.1%/99.9% total HbSS sensitivity/specificity. Overall, HemoTypeSC exhibited sensitivity and specificity of 98.1% and 99.1% for all possible phenotypes (HbAA, HbAS, and HbSS) detected. HPLC is relatively expensive and not available in most laboratories in remote tribal areas. Conclusions We conclude that the rapid, point-of-care testing device HemoTypeSC test is suitable for population and newborn screening for the HbS phenotype.

Accuracy of Point-of-care Lung Ultrasonography for Diagnosis of Acute Chest Syndrome in Pediatric Patients with Sickle Cell Disease and Fever

2016 ◽  
Vol 23 (8) ◽  
pp. 932-940 ◽  
Author(s):  
Dina D. Daswani ◽  
Vaishali P. Shah ◽  
Jeffrey R. Avner ◽  
Deepa G. Manwani ◽  
Jessica Kurian ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Pediatric Patients ◽  
Point Of Care ◽  
Acute Chest Syndrome ◽  
Lung Ultrasonography ◽  
Cell Disease

scholarly journals Point-of-Care Screening for Sickle Cell Disease By a Mobile Micro-Electrophoresis Platform

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3379-3379 ◽  
Author(s):  
Ryan Ung ◽  
Yunus Alapan ◽  
Muhammad Noman Hasan ◽  
Megan Romelfanger ◽  
Ping He ◽  
...  
Keyword(s):  
Image Processing ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Operating Characteristic ◽  
Point Of Care ◽  
Cell Disease ◽  
Web Based ◽  
Processing Application ◽  
Image Processing Application ◽  
Objective Quantification

Abstract In developing countries, diagnostic tests for homozygous (HbSS) or compound heterozygous (HbSC or HbS-Beta thalassemia) sickle cell disease (SCD) are not readily available at the point-of-care (POC). Very few infants are screened in Africa for SCD because of the high cost and level of skill needed to run traditional tests. Current methods are too costly and take too much time to enable equitable and timely diagnosis to save lives. The World Health Organization recognizes a crucial need for early detection of SCD in newborns, since it is estimated that 70% SCD-related deaths in Africa are preventable with early cost-effective interventions. The diagnostic barrier can be broken with affordable, POC tools that facilitate early detection immediately after birth. We have developed a mobile micro-electrophoretic device (HemeChip) through which to quickly, accurately, and affordably screen for SCD (Fig. 1A). The HemeChip uses a microfabricated platform housing cellulose acetate electrophoresis to rapidly separate hemoglobin (Hb) types. Less than 5 microliters of blood, which can be obtained through a finger stick or heel stick, is processed on a piece of cellulose paper in alkaline buffer. The HemeChip reliably identifies and discriminates amongst Hb C/A2, S, F and A0. The micro-electrophoresis results were validated against standard clinical hemoglobin screening methods, including high performance liquid chromatography (HPLC), with Pearson Correlation Coefficient (PCC) of ≥0.96 relative to HPLC for all Hb types tested. The receiver Operating-Characteristic (ROC) curves showed more than 0.89 sensitivity and 0.86 specificity for identification of hemoglobin types using the HemeChip, based on the travelling distance from the sample application point (Fig. 1B). We developed a web-based image processing application for automated and objective quantification of HemeChip results at the POC using cloud computing resources (Fig. 1C). This intensity-based mobile phone image quantitation method showed high correlation with HPLC results for tested patient blood samples (PCC=0.95). HemeChip can distinguish between different patient phenotypes, including HbSS (HbS only), transfused HbSS (HbS and HbA), and Hemoglobin SC disease (HbS and HbC). In conclusion, the HemeChip identification and quantification of hemoglobin phenotypes, as a POC technique, were comparable to standard clinical methods. This platform has clinical potential in under-served populations worldwide, in which SCD is endemic. Figure 1. Mobile micro-electrophoretic device (HemeChip) for point-of-care screening for sickle cell disease. ( A) HemeChip prototype is shown with a miniscule blood sample that has been separated into characteristic hemoglobin bands. (B) The receiver Operating-Characteristic (ROC) curves show sensitivity and specificity of HemeChip for differentiating between adjacent hemoglobin bands based on the travelling distance from the sample application point. band traveling distance thresholds are shown: circle=7.5 mm, triangle=10.0 mm, and square=12.5 mm. (C) Web-based image processing application for automated and objective quantification of HemeChip results at the POC using cloud computing resources. Figure 1. Mobile micro-electrophoretic device (HemeChip) for point-of-care screening for sickle cell disease. ( A) HemeChip prototype is shown with a miniscule blood sample that has been separated into characteristic hemoglobin bands. (B) The receiver Operating-Characteristic (ROC) curves show sensitivity and specificity of HemeChip for differentiating between adjacent hemoglobin bands based on the travelling distance from the sample application point. band traveling distance thresholds are shown: circle=7.5 mm, triangle=10.0 mm, and square=12.5 mm. (C) Web-based image processing application for automated and objective quantification of HemeChip results at the POC using cloud computing resources. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document